JELMYTO® Shows 86% Recurrence-Free Survival (RFS) at 24 Months: Real-World AUA 2024 Analysis

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company specializing in urothelial and specialty cancer treatments, presents findings from a sub-analysis of JELMYTO (mitomycin) for pyelocalyceal solution at the American Urological Association Meeting 2024. In a cohort of complete responders to…

Read MoreJELMYTO® Shows 86% Recurrence-Free Survival (RFS) at 24 Months: Real-World AUA 2024 Analysis

Smart Meter Launches Cellular Glucose Meter with Notifications & Multi-Language Features

Smart Meter, a leading provider of Cellular Remote Patient Monitoring (RPM) solutions, has launched the iGlucose Plus, an upgraded version of its popular cellular-connected glucose meter. With its innovative features, the iGlucose Plus aims to revolutionize remote blood glucose monitoring…

Read MoreSmart Meter Launches Cellular Glucose Meter with Notifications & Multi-Language Features

Advancing Neuroscience with GE HealthCare’s SIGNA MAGNUS

Today, GE HealthCare (Nasdaq: GEHC) introduced SIGNA MAGNUS, a head-only magnetic resonance (MR) scanner awaiting FDA 510(k) approval. It’s specifically crafted to propel advancements in neuroscience, addressing limitations of conventional whole-body MR systems. Neuroscience, especially in researching psychiatric conditions and…

Read MoreAdvancing Neuroscience with GE HealthCare’s SIGNA MAGNUS

Mars, Inc. in Exclusive Talks to Acquire Cerba Vet and ANTAGENE from Cerba HealthCare

Today, Mars, Incorporated revealed it’s in exclusive talks with Cerba HealthCare, aiming to acquire Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE Based in Massy, France, Cerba Vet operates six veterinary diagnostics laboratories in France and Switzerland. With about…

Read MoreMars, Inc. in Exclusive Talks to Acquire Cerba Vet and ANTAGENE from Cerba HealthCare

Study: JELMYTO® Retrograde Instillation Shows Comparable Results to OLYMPUS Trial

UroGen Pharma Ltd. (Nasdaq: URGN), specializing in innovative treatments for urothelial and specialty cancers, highlights findings from a sub-analysis of real-world patient data on JELMYTO (mitomycin) for pyelocalyceal solution. Presented at the American Urological Association Meeting 2024 in San Antonio,…

Read MoreStudy: JELMYTO® Retrograde Instillation Shows Comparable Results to OLYMPUS Trial